Annexon expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy by adding an independent 24-month dual primary endpoint while maintaining its planned fourth-quarter assessment of the existing 15-month endpoint. The company remains on track to submit a U.S. Biologics License Application for tanruprubart in Guillain-Barré syndrome in the fourth quarter. In an initial 10-patient FORWARD cohort, all patients experienced clinically meaningful muscle-strength improvement within four days, though the results are preliminary. Annexon also secured access to up to $200 million in non-dilutive financing through an Oxford Finance credit facility, extending its cash runway into 2028 as both lead programs approach regulatory and clinical milestones. The full ARCHER II study, including 24-month analyses, is expected to conclude in the third quarter of 2027.
Annexon IncSecured up to $200M non-dilutive financing, extending cash runway into 2028.
